abs414.txt	background		breast	cancer	patients	with	estrogen	receptor	(er)-positive	diseasehave	a	continuous	long-term	risk	for	fatal	but	the	biologicalfactors	influencing	this	are	unknown	we	aimed	to	determine	whether	highintratumor	heterogeneity	of	er	predicts	an	increased	(25	years)	offatal	methods	sto-3	trial	enrolled	1780	postmenopausal	lymph	node-negative	breastcancer	randomly	assigned	receive	adjuvant	tamoxifen	vs	not	thefraction	cells	each	intensity	level	was	scored	by	cancerpathologists	and	intratumor	calculated	using	rao'squadratic	entropy	categorized	into	high	low	apredefined	cutoff	at	second	tertile	(67%)	cancer-specificsurvival	analyses	intra-tumor	were	performed	usingkaplan-meier	multivariable	cox	proportional	hazard	modeling	adjusting	forpatient	tumor	characteristics	results	statistically	significant	difference	in	survival	vslow	seen	all	er-positive	(p	<	001)	luminal	subtype	tumors	=	01)	multivariableanalyses	had	twofoldincreased	as	compared	intratumorheterogeneity	(er-positive	ratio	[hr]	1	98	95%	confidence	interval[ci]	31	3	00	hr	2	43	ci	18	4	99)	conclusions	increasedlong-term	interestingly	similar	riskincrease	our	findings	suggestthat	is	independent	prognosticatorwith	potential	change	clinical	management	especially	withluminal
